Currently, 6 FDA-approved CAR T cell therapies targeting CD19 and B cell maturation antigen (BCMA) are utilized for treating hematologic cancers, and there is ongoing development of CAR T cell therapies aimed at solid tumors and other severe diseases [11]. This evidence concerns the gene TNFRSF17 and hematopoietic and lymphoid cell neoplasm.